Sign In
Buy CRIS
$1.23
-0.100 (-7.52%)
At Close: Nov 17, 2025
Curis to Present at Upcoming 30th Annual SNO Meeting
09:26am, Friday, 14'th Nov 2025
LEXINGTON, Mass. , Nov. 14, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhi
Curis, Inc. (CRIS) Q3 2025 Earnings Call Transcript
01:56pm, Friday, 07'th Nov 2025
Curis, Inc. ( CRIS ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Diantha Duvall - CFO and Principal Financial & Accounting Officer James Dentzer - President, CEO, Secretary
Curis (CRIS) Reports Q3 Loss, Beats Revenue Estimates
06:11pm, Thursday, 06'th Nov 2025
Curis (CRIS) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to a loss of $1.7 per share a year ago.
Curis Provides Third Quarter 2025 Business Update
04:00pm, Thursday, 06'th Nov 2025
Management to host conference call and webcast today at 4:30 p.m. ET LEXINGTON, Mass.
Curis to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025
04:00pm, Thursday, 30'th Oct 2025
LEXINGTON, Mass. , Oct. 30, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhi
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:00pm, Friday, 03'rd Oct 2025
LEXINGTON, Mass. , Oct. 3, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhi
Curis, Inc. (CRIS) Presents At Cantor Global Healthcare Conference 2025 Transcript
09:45am, Friday, 12'th Sep 2025
Curis, Inc. (NASDAQ:CRIS ) Cantor Global Healthcare Conference 2025 September 5, 2025 9:45 AM EDT Company Participants James Dentzer - President, CEO, Secretary, Treasurer & Director Conference Call P
Curis, Inc. (CRIS) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript
05:20am, Thursday, 11'th Sep 2025
Curis, Inc. (NASDAQ:CRIS ) H.C. Wainwright 27th Annual Global Investment Conference September 10, 2025 10:00 AM EDT Company Participants James Dentzer - President, CEO, Secretary, Treasurer & Director
Curis to Present at Upcoming Healthcare Conferences in September
10:43am, Tuesday, 02'nd Sep 2025
LEXINGTON, Mass. , Sept. 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhi
Curis (CRIS) Q2 Loss Narrows 66%
06:10pm, Tuesday, 05'th Aug 2025
Curis (CRIS 4.38%), a biotechnology company focused on developing targeted cancer therapies, reported its earnings for the second quarter of 2025 on August 5, 2025. Curis reported a GAAP net loss of $
Curis, Inc. (CRIS) Q2 2025 Earnings Call Transcript
11:25am, Tuesday, 05'th Aug 2025
Curis, Inc. (NASDAQ:CRIS ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Ahmed M. Hamdy - Chief Medical Officer Diantha Duvall - CFO and Principal Financial & Account
Curis (CRIS) Reports Q2 Loss, Beats Revenue Estimates
10:11am, Tuesday, 05'th Aug 2025
Curis (CRIS) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $1.99. This compares to a loss of $2.03 per share a year ago.
Curis Provides Second Quarter 2025 Business Update
08:00am, Tuesday, 05'th Aug 2025
Management to host conference call and webcast today at 8:30 a.m. ET LEXINGTON, Mass.
Curis to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2025
08:30am, Tuesday, 29'th Jul 2025
LEXINGTON, Mass. , July 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhi
Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement
08:32am, Wednesday, 02'nd Jul 2025
LEXINGTON, Mass. , July 2, 2025 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule I
